#eli-lilly

[ follow ]
Photography
fromFast Company
8 hours ago

Eli Lilly signs $1.3 billion deal with Superluminal to use AI to make obesity medicines

Eli Lilly has signed a $1.3 billion deal with Superluminal Medicines to develop AI-driven drugs targeting obesity and cardiometabolic diseases.
#mounjaro
more#mounjaro
#weight-loss
more#weight-loss
#orforglipron
fromwww.nytimes.com
3 months ago
Wearables

What to Know About Eli Lilly's Daily Pill for Weight Loss

Eli Lilly's orforglipron offers a potential oral treatment for obesity and diabetes, expanding access beyond current injected options.
fromBusiness Insider
3 months ago
Wearables

Weight loss in a pill? Eli Lilly just took a big step closer to making it happen

Orforglipron, a new oral GLP-1 drug from Eli Lilly, may transform obesity treatment by offering a non-injection alternative.
Wearables
fromNew York Post
3 months ago

Everything to know about the new weight loss pill that works as well as Ozempic - and when you can get it

Eli Lilly's orforglipron offers a stab-free treatment for diabetes and obesity, with potential FDA approval enhancing its market presence.
Wearables
fromwww.nytimes.com
3 months ago

What to Know About Eli Lilly's Daily Pill for Weight Loss

Eli Lilly's orforglipron offers a potential oral treatment for obesity and diabetes, expanding access beyond current injected options.
Wearables
fromBusiness Insider
3 months ago

Weight loss in a pill? Eli Lilly just took a big step closer to making it happen

Orforglipron, a new oral GLP-1 drug from Eli Lilly, may transform obesity treatment by offering a non-injection alternative.
more#orforglipron
Miscellaneous
fromBusiness Insider
1 month ago

Eli Lilly's 3-step strategy to dominate the $95 billion obesity market

Eli Lilly is becoming the leader in weight loss drugs, surpassing competitors like Novo Nordisk. Their drug portfolio is innovative and expansive.
fromFast Company
1 month ago

Eli Lilly is making it cheaper and easier to buy high-doses of blockbuster weight-loss drug Zepbound

"Obesity is a serious, chronic disease, and access to obesity medications should be treated with the same urgency as other chronic conditions," said Rhonda Pacheco, emphasizing the importance of medication access.
Wearables
#pharmaceuticals
more#pharmaceuticals
Startup companies
from24/7 Wall St.
2 months ago

Visa, Eli Lilly or Netflix- Which Stock Will Be A Trillion Dollar Company Next?

Visa, Netflix, and Eli Lilly are contenders for the trillion-dollar club, each poised for significant market growth.
Intellectual property law
fromAbove the Law
2 months ago

Patenting Privation (Part III): Empowering Revenge - Above the Law

The FDA's lifting of the shortage declaration has curtailed bulk sales of competing diabetes medications, impacting telehealth revenues significantly.
#novo-nordisk
more#novo-nordisk
London startup
from24/7 Wall St.
3 months ago

Eli Lilly Will Be the Next $1 Trillion Stock

Eli Lilly aims to become the first healthcare company with a $1 trillion market cap, spurred by its GLP-1 therapy leadership.
Orforglipron's success in trials positions Lilly for significant market growth in obesity and diabetes management.
fromwww.npr.org
3 months ago

Eli Lilly sues companies selling alternative versions of its weight loss drug

Eli Lilly is suing four telehealth companies for selling illegal copies of its weight-loss drug Zepbound, which is based on the active ingredient tirzepatide.
Alternative medicine
from24/7 Wall St.
3 months ago

Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (April 2025)

From late 2020 to the summer of 2024, Eli Lilly & Co. stock surged over 635%, driven by innovative medicines and regulatory successes, despite recent revenue shortfalls.
London startup
Cryptocurrency
from24/7 Wall St.
3 months ago

Here's Why Eli Lilly (NYSE: LLY). Fidelity National (NYSE: FIS) and Diamondback Energy (Nasdaq: FANG) Are Soaring Today

Market reactions are mixed due to President Trump's comments about the Federal Reserve, impacting the Dow Jones and S&P 500 differently.
Eli Lilly's new diabetes drug shows promising results, significantly boosting its stock value.
fromNew York Post
3 months ago

Eli Lilly stock surges 15% after clinical trial of weight loss pill shows it works like Ozempic

"The drug also lowered patients' blood sugar levels by 1.3% on average, while the overall efficacy of orforglipron in promoting weight loss and controlling diabetes has been met with enthusiasm."
Wearables
from24/7 Wall St.
3 months ago

These 2 Dividend Giants Are at 52-Week Lows. Time to Buy?

That's where being a savvy investor comes in. Being contrarian, you can pick up these hidden gems at a significant discount and profit all the way to the bank when their fortunes turn.
Startup companies
[ Load more ]